NEW YORK, NY / ACCESS Newswire / February 12, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...

From revenue to R&D investment, Novo and Lilly and their mega-blockbuster weight loss drugs Zepbound and Wegovy have moved ...

Novo Nordisk announced plans for a longer phase III trial testing its investigational obesity drug CagriSema, with regulatory ...

Novo Nordisk faces challenges but its pipeline remains strong. Find out why NVO stock could deliver high double-digit returns ...

Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has bee ...

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

Ken Fisher is the founder and executive chairman of Fisher Asset Management, a renowned investment and financial analysis ...

Novo Nordisk shares tumbled last year when obesity candidate CagriSema failed to clear a weight loss bar of 25%. Now, ...

European Opportunities Trust invests in European companies offering capital growth and is managed by Devon Equity Management Ltd. The company said net asset value per share fell 8.6% to 921.66 pence ...

CagriSema, considered a successor to Wegovy, is Novo Nordisk’s most likely route of gaining GLP-1RA market share back from ...